Robert A. Fromtling - Concepedia

Author

Robert A. Fromtling

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Fromtling, R.A., R A Fromtling, R. A. FROMTLING, R. A. Fromtling, R.A. Fromtling, ROBERT A. FROMTLING, ROBERT FROMTLING, Robert A. Fromtling, Robert. A. Fromtling

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Virginia Commonwealth University Medical Center University of Oklahoma Health Sciences Center University of Puerto Rico-Mayaguez

About

Robert A. Fromtling is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, microbiology, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	30	1.4K
2	Health Sciences	3	3	287
3	Natural Sciences	3	3	76
4	Engineering	1	1	16
5	Public Health	1	1	22

Robert A. Fromtling

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Recent Trends in the Discovery, Development, and Evaluation of Antifungal Agents Robert A. Fromtling, Phyllis C. Braun, Richard Hector DigitalCommons - Fairfield (Fairfield University)	1987	478
Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests Ana Espinel‐Ingroff, Charles W. Kish, Thomas M. Kerkering, Journal of Clinical Microbiology	1992	244
Decreased virulence in stable, acapsular mutants ofCryptococcus neoformans Robert A. Fromtling, H. Jean Shadomy, E S Jacobson Mycopathologia Virulence FactorBacteriologyAcapsular MutantsMicrobiologyMolecular Microbiology	1982	209
Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts Robert A. Fromtling, J N Galgiani, Michael A. Pfaller, Antimicrobial Agents and Chemotherapy MycologyDiagnostic MycologyAntifungal AgentAntimicrobial SusceptibilityAntifungal Agents	1993	198
Collaborative investigation of variables in susceptibility testing of yeasts Michael A. Pfaller, Michael G. Rinaldi, J N Galgiani, Antimicrobial Agents and Chemotherapy Test MediumAntifungal AgentHealth SciencesSusceptibility TestingAntifungal Agents	1990	189
Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Dennis M. Schmatz, M A Romancheck, L A Pittarelli, Proceedings of the National Academy of Sciences Medicinal ChemistryCyst FormAntibioticsAntiparasitic AgentPharmacology	1990	160
Cryptococcus neoformans: size range of infectious particles from aerosolized soil J. B. Neilson, Robert A. Fromtling, Glenn S. Bulmer Infection and Immunity Pathogenic MicrobiologyMicrobial DiseaseAerobiologyPathogen TransmissionExtremophile	1977	123
L-657,398, a novel antifungal agent: Fermentation, isolation, structural elucidation and biological properties. Robert E. Schwartz, Jerrold M. Liesch, Otto D. Hensens, The Journal of Antibiotics	1988	100
Sphingofungins A,B,C, and d; a new family of antifungal agents. I. Fermentation, isolation, and biological activity. Frank VanMiddlesworth, R.A. Giacobbe, María Ofelia López, The Journal of Antibiotics	1992	97
Distribution of Cryptococcus neoformans in a natural site A. Ruiz, Robert A. Fromtling, Glenn S. Bulmer Infection and Immunity BiologyVacant TowerMicrobial DiversityPathogenic MicrobiologyAerobiology	1981	91

Page 1